Table 2: Risk of bias in included randomized controlled trials.

StudyRandom sequence generationAllocation concealmentBlinding of participants and personnelBlinding of outcome assessmentIncomplete outcome dataSelective reportingOther sources of bias

Cappi 2012 [14]Low riskLow riskHigh riskLow riskLow riskLow riskLow risk
COIITSS 2010 (France) [16]Low riskLow riskHigh riskLow riskLow riskLow riskHigh riska
Savioli 2009 [12]Low riskUnclearHigh riskLow riskLow riskLow riskLow risk
Iapichino 2008 [11]Low riskUnclearHigh riskHigh riskLow riskUnclearLow risk
Brunkhorst 2008 [10]Low riskLow riskHigh riskHigh riskLow riskLow riskHigh riska,b
Ellger 2008 [25]Low riskLow riskHigh riskLow riskLow riskLow riskLow risk
Yu 2005 [13]UnclearUnclearHigh riskLow riskLow riskHigh riskLow risk
Dong 2009 [27]UnclearUnclearHigh riskHigh riskLow riskUnclearLow risk
NICE-SUGAR 2009 (Australia and New Zealand—Canada) [17] Low riskLow riskHigh riskLow riskLow riskLow riskHigh riskc
Arabi 2008 [24]Low riskLow riskHigh riskLow riskLow riskLow riskHigh riskd
Zhang 2008 [26]UnclearUnclearHigh riskLow riskLow riskUnclearLow risk
Jin 2009* [23]NANANANANANANA

Abstract only.
NA: not available from article or author.
The two treatment groups differ in the use of medications other than insulin.
Intensive insulin therapy was terminated early because of increasing hypoglycemic events.
Inclusion used subjective criteria.
It had a different baseline.